DexCom Stock Plunged Over 40% Last Week. Are Eli Lilly's and Novo Nordisk's Drugs to Blame?

DexCom faces several challenges, but GLP-1 drugs aren't big problems for the company right now.Going into 2024, DexCom's (DXCM 5.44%) shares were up a whopping 14 times over the last 10 years. The company's continuous glucose monitoring (CGM) devices enjoyed tremendous demand from individuals with diabetes.However, last week was the worst for DexCom stock since the company's initial public offering (IPO) in April 2005. Shares of the medical device maker plunged over 40% following DexCom's second-quarter upd ...